异基因移植后使用达雷妥尤单抗成功治疗血小板减少症：一例病例报告及文献综述
Successful treatment of thrombocytopenia with daratumumab after allogeneic transplant: a case report and literature review.
作者信息
Migdady Yazan, Ediriwickrema Asiri, Jackson Ryan Patrick, Kadi Wendy, Gupta Ridhi, Socola Francisco, Arai Sally, Martin Beth A
机构信息
Stanford University, Stanford, CA.
Division of Hematology, Stanford University School of Medicine, Stanford, CA.
出版信息
Blood Adv. 2020 Mar 10;4(5):815-818. doi: 10.1182/bloodadvances.2019001215.
Abstract
A source of treatment refractoriness in immune cytopenias appears to be residual CD138/38-positive lymphocyte populations. A short course of daratumumab is a novel treatment of refractory thrombocytopenia after failure of standard treatment options.
摘要
免疫性血细胞减少症治疗难治的一个原因似乎是残留的CD138/38阳性淋巴细胞群体。在标准治疗方案失败后，短期使用达雷妥尤单抗是治疗难治性血小板减少症的一种新方法。
相似文献
1
Successful treatment of thrombocytopenia with daratumumab after allogeneic transplant: a case report and literature review.异基因移植后使用达雷妥尤单抗成功治疗血小板减少症：一例病例报告及文献综述
Blood Adv. 2020 Mar 10;4(5):815-818. doi: 10.1182/bloodadvances.2019001215.
2
Post-allogeneic transplant Evans syndrome successfully treated with daratumumab.达雷妥尤单抗成功治疗异基因移植后埃文斯综合征
Br J Haematol. 2019 Oct;187(2):e48-e51. doi: 10.1111/bjh.16171. Epub 2019 Aug 23.
3
Daratumumab for the management of autoimmune cytopenias in children and young adults: a case series.达雷妥尤单抗用于儿童和青年自身免疫性血细胞减少症的治疗：病例系列
Br J Haematol. 2021 Sep;194(5):e84-e89. doi: 10.1111/bjh.17565. Epub 2021 May 27.
4
Successful upfront cord blood transplantation for plasma cell leukemia in the first complete response after daratumumab therapy.达雷妥尤单抗治疗后首次完全缓解时进行的成功 upfront 脐带血移植治疗浆细胞白血病。
Int J Hematol. 2021 Jun;113(6):941-944. doi: 10.1007/s12185-021-03082-1. Epub 2021 Jan 22.
5
Successful treatment of refractory red cell aplasia after allogeneic hematopoietic cell transplantation with daratumumab.达雷妥尤单抗治疗异基因造血细胞移植后难治性红细胞再生障碍的疗效。
Eur J Haematol. 2020 Feb;104(2):145-147. doi: 10.1111/ejh.13343. Epub 2019 Nov 20.
6
Daratumumab for pure red cell aplasia post ABO incompatible allogeneic hematopoietic stem cell transplant for aplastic anemia.达雷妥尤单抗治疗再生障碍性贫血患者 ABO 不合异基因造血干细胞移植后纯红细胞再生障碍。
Blood Cells Mol Dis. 2021 May;88:102464. doi: 10.1016/j.bcmd.2020.102464. Epub 2020 Jul 2.
7
Daratumumab for Delayed Red-Cell Engraftment after Allogeneic Transplantation.达雷妥尤单抗治疗异基因移植后红细胞植入延迟。
N Engl J Med. 2018 Nov 8;379(19):1846-1850. doi: 10.1056/NEJMoa1807438.
8
Risk of thromboembolism in patients with multiple myeloma treated with daratumumab: a systemic review and meta-analysis.达雷妥尤单抗治疗的多发性骨髓瘤患者发生血栓栓塞的风险：一项系统评价和荟萃分析。
Int J Hematol. 2020 Nov;112(5):650-657. doi: 10.1007/s12185-020-02954-2. Epub 2020 Jul 24.
9
Successful treatment with daratumumab for post-HSCT refractory hemolytic anemia.达雷妥尤单抗治疗异基因造血干细胞移植后难治性溶血性贫血的疗效。
Pediatr Blood Cancer. 2020 Jan;67(1):e28010. doi: 10.1002/pbc.28010. Epub 2019 Sep 22.
10
Refractory postallogeneic stem cell transplant pure red cell aplasia in remission after treatment with daratumumab.达雷妥尤单抗治疗后缓解的难治性异基因干细胞移植后纯红细胞再生障碍性贫血
Am J Hematol. 2019 Aug;94(8):E216-E219. doi: 10.1002/ajh.25515. Epub 2019 Jun 7.
引用本文的文献
1
Effective treatment with daratumumab in post-HSCT refractory immune-mediated cytopenias: a case report and literature review.达雷妥尤单抗治疗异基因造血干细胞移植后难治性免疫介导血细胞减少症的有效性：一例报告及文献综述
Front Immunol. 2025 Aug 1;16:1625365. doi: 10.3389/fimmu.2025.1625365. eCollection 2025.
2
Teclistamab-Induced Remission of Chronic Immune Thrombocytopenia in a Patient With Multiple Myeloma.泰吉华（teclistamab）诱导一名多发性骨髓瘤患者的慢性免疫性血小板减少症缓解
EJHaem. 2025 May 25;6(3):e70062. doi: 10.1002/jha2.70062. eCollection 2025 Jun.
3
Daratumumab and Romiplostim Combined Therapy for a Long-Standing Refractory Primary Immune Thrombocytopenia - Case Report.达雷妥尤单抗与罗米司亭联合治疗长期难治性原发性免疫性血小板减少症——病例报告
Immunotargets Ther. 2025 Jan 6;14:1-5. doi: 10.2147/ITT.S487895. eCollection 2025.
4
Isatuximab for Delayed Red Cell Engraftment after Allogeneic Hematopoietic Cell Transplantation.isatuximab用于异基因造血细胞移植后红细胞延迟植入
Case Rep Hematol. 2024 Aug 30;2024:5790011. doi: 10.1155/2024/5790011. eCollection 2024.
5
Graves-PCD: protocol for a randomised, dose-finding, adaptive trial of the plasma cell-depleting agent daratumumab in severe Graves' disease.Graves-PCD 研究：随机、剂量探索、适应性临床试验方案，评估在严重 Graves 病中使用浆细胞耗竭剂达雷妥尤单抗的效果。
BMJ Open. 2024 Jun 12;14(6):e079158. doi: 10.1136/bmjopen-2023-079158.
6
Transfusion Support in Hematopoietic Stem Cell Transplantation: A Contemporary Narrative Review.造血干细胞移植中的输血支持：当代叙述性综述
Clin Hematol Int. 2024 Mar 25;6(1):128-140. doi: 10.46989/001c.94135. eCollection 2024.
7
Identification of metabolism-related key genes as potential biomarkers for pathogenesis of immune thrombocytopenia.鉴定代谢相关关键基因作为免疫性血小板减少症发病机制的潜在生物标志物。
Sci Rep. 2024 Apr 19;14(1):9040. doi: 10.1038/s41598-024-59493-7.
8
Rituximab resistance in ITP and beyond.ITP 及其他疾病中的利妥昔单抗耐药。
Front Immunol. 2023 Jul 28;14:1215216. doi: 10.3389/fimmu.2023.1215216. eCollection 2023.
9
B-cell targeting with anti-CD38 daratumumab: implications for differentiation and memory responses.B 细胞靶向治疗抗 CD38 达雷妥尤单抗：对分化和记忆应答的影响。
Life Sci Alliance. 2023 Jul 7;6(9). doi: 10.26508/lsa.202302214. Print 2023 Sep.
10
Anti-HLA Class I alloantibodies in platelet transfusion refractoriness: From mechanisms and determinants to therapeutic prospects.血小板输注无效中的抗 HLA Ⅰ类同种抗体：从机制和决定因素到治疗前景。
Front Immunol. 2023 Feb 9;14:1125367. doi: 10.3389/fimmu.2023.1125367. eCollection 2023.
本文引用的文献
1
Post-allogeneic transplant Evans syndrome successfully treated with daratumumab.达雷妥尤单抗成功治疗异基因移植后埃文斯综合征
Br J Haematol. 2019 Oct;187(2):e48-e51. doi: 10.1111/bjh.16171. Epub 2019 Aug 23.
2
Daratumumab for Delayed Red-Cell Engraftment after Allogeneic Transplantation.达雷妥尤单抗治疗异基因移植后红细胞植入延迟。
N Engl J Med. 2018 Nov 8;379(19):1846-1850. doi: 10.1056/NEJMoa1807438.
3
Daratumumab in life-threatening autoimmune hemolytic anemia following hematopoietic stem cell transplantation.达雷妥尤单抗治疗造血干细胞移植后危及生命的自身免疫性溶血性贫血。
Blood Adv. 2018 Oct 9;2(19):2550-2553. doi: 10.1182/bloodadvances.2018020883.
4
Successful treatment of pure red cell aplasia because of ABO major mismatched stem cell transplant.ABO主要错配干细胞移植所致纯红细胞再生障碍性贫血的成功治疗
J Clin Apher. 2018 Feb;33(1):108-112. doi: 10.1002/jca.21553. Epub 2017 May 24.
5
Persistence of recipient human leucocyte antigen (HLA) antibodies and production of donor HLA antibodies following reduced intensity allogeneic haematopoietic stem cell transplantation.受者人类白细胞抗原（HLA）抗体的持续存在和降低强度同种异体造血干细胞移植后供者 HLA 抗体的产生。
Br J Haematol. 2014 Aug;166(3):425-34. doi: 10.1111/bjh.12890. Epub 2014 Apr 18.
6
B cell depletion in immune thrombocytopenia reveals splenic long-lived plasma cells.在免疫性血小板减少症中 B 细胞耗竭揭示了脾脏长寿命浆细胞。
J Clin Invest. 2013 Jan;123(1):432-42. doi: 10.1172/JCI65689. Epub 2012 Dec 17.
7
Immunologic effects of rituximab on the human spleen in immune thrombocytopenia.利妥昔单抗对免疫性血小板减少症患者脾脏的免疫作用。
Blood. 2011 Oct 20;118(16):4394-400. doi: 10.1182/blood-2011-03-344051. Epub 2011 Aug 29.
8
Successful treatment of isohemagglutinin-mediated pure red cell aplasia after ABO-mismatched allogeneic hematopoietic cell transplant using bortezomib.使用硼替佐米成功治疗ABO血型不匹配的异基因造血细胞移植后同种血凝素介导的纯红细胞再生障碍。
Bone Marrow Transplant. 2012 Jun;47(6):870-1. doi: 10.1038/bmt.2011.176. Epub 2011 Aug 29.
9
Development of a secondary autoimmune disorder after hematopoietic stem cell transplantation for autoimmune diseases: role of conditioning regimen used.自身免疫性疾病造血干细胞移植后继发性自身免疫性疾病的发生：所采用预处理方案的作用
Blood. 2007 Mar 15;109(6):2643-548. doi: 10.1182/blood-2006-07-035766. Epub 2006 Nov 21.
10
Clinically significant newly presenting autoimmune thrombocytopenic purpura in adults: a prospective study of a population-based cohort of 245 patients.
Br J Haematol. 2003 Sep;122(6):966-74. doi: 10.1046/j.1365-2141.2003.04547.x.
Zotero 插件